• Users Online: 202
  • Print this page
  • Email this page
REVIEW ARTICLE
Year : 2022  |  Volume : 6  |  Issue : 2  |  Page : 164-169

Itraconazole and posaconazole from antifungal to antiviral drugs


Department of Medical Laboratory Technology, College of Medical Technology, The Islamic University, Najaf, Iraq

Correspondence Address:
Falah Hasan Obayes AL-Khikani
Department of Medical Laboratory Technology, College of Medical Technology, The Islamic University, Najaf
Iraq
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/bbrj.bbrj_242_21

Rights and Permissions

The extended spectrum of antifungal triazole such as posaconazole (POS) and itraconazole (ITZ) shows the active efficacy for prophylaxis and treatment of an invasive fungal infection that may cause various infections such as respiratory diseases. Active azoles' derivatives, especially POS and ITZ, with high biological efficacy and low toxicity have made new advances in azoles' compounds as antimicrobials. Recently, some studies focused on the potential antimicrobial action of POS and ITZ against some viruses such as influenza A virus, Ebola virus, and enteroviruses. In general, new treatment research is needed due to the continued expansion of viral diseases and the exponential growth in mortality rates. By discussing the most recent information about the antiviral action of POS and ITZ against certain viral infections, as well as attempting to gain a deep understanding of the major properties, mechanisms of action, immune system responses, and antimicrobial activity of POS and ITZ, this review may serve as an impetus for researchers working in the field of medical microbiology and antiviral drug design. Since the antiviral activity of POS and ITZ against various viruses by different mechanisms of actions including enveloped viral infection, besides its other unique properties such as prophylactic feature and host immunomodulatory effects, as a result of our review, it appears that POS and ITZ, as effective antifungi drugs, may offer the possibility of developing a novel therapeutic alternative or synergistic treatment for certain viruses.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed220    
    Printed4    
    Emailed0    
    PDF Downloaded24    
    Comments [Add]    

Recommend this journal